Cover Image

A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system

PurposeSacubitril/valsartan is extensively used in heart failure; however, there are few long-term safety studies of it in a wide range of populations. The aim of this study was to evaluate sacubitril/valsartan-induced adverse events (AEs) through data mining of the U.S. Food and Drug Administration...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yiwen Wang (Author), Xuna Liu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
by: Zhihong Fang, et al.
Published: (2023)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024)

A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system
by: Kaixuan Wang, et al.
Published: (2024)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
by: Yue He, et al.
Published: (2024)

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2023)

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system
by: Jun Shen, et al.
Published: (2024)

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system
by: Wei Wei, et al.
Published: (2024)

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System
by: Huqun Li, et al.
Published: (2024)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024)

Sacubitril/valsartan in real-life clinical practice
by: Yüksel Çavuşoğlu
Published: (2021)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022)

Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2024)

Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS)
by: Wenqiang Kong, et al.
Published: (2023)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022)

A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
by: Liyuan Liu
Published: (2024)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
by: Haoning Guo, et al.
Published: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
by: Yankun Liang, et al.
Published: (2023)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2023)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
by: Qiang Guo, et al.
Published: (2022)

Detection of muscular system adverse reaction signals in sacubitril/valsartan treatment combined with statins
by: Fukun Zhao, et al.
Published: (2024)

A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
by: Weizhen He, et al.
Published: (2024)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020)

Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database
by: Wei Wang, et al.
Published: (2023)

A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)
by: Jie Zhou, et al.
Published: (2024)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
by: Xusheng Zhang, et al.
Published: (2024)

Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
by: Cuthbert JJ, et al.
Published: (2020)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
by: Feifei Wang, et al.
Published: (2022)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022)

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Jiahong Zhong, et al.
Published: (2024)

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Zhengkang Su, et al.
Published: (2024)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023)

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023
by: Jinger Lin, et al.
Published: (2024)

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system
by: Qiong Jie, et al.
Published: (2024)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023)

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database
by: Yichun Shuai, et al.
Published: (2024)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018)

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
by: Dan Liu, et al.
Published: (2024)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
by: Xue-Feng Jiao, et al.
Published: (2023)